ArQule, Inc. (ARQL)
(Delayed Data from NSDQ)
$6.51 USD
+0.23 (3.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.51 USD
+0.23 (3.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Exelixis (EXEL) Poised for a Beat Again in Q2?
by Zacks Equity Research
Exelixis (EXEL) is likely to beat earnings again in the second quarter, driven by favourable metrics. Investors will focus on the company's uptake in the first-line RCC setting, along with other updates.
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte (INCY) has a mixed track record. Investors will focus on Jakafi sales and other pipeline updates when the company reports its Q2 results on Jul 31.
Has ArQule (ARQL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ARQL) Outperforming Other Medical Stocks This Year?
Options Traders Expect Huge Moves in ArQule (ARQL) Stock
by Zacks Equity Research
ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.
Will ArQule (ARQL) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in ArQule, Inc. (ARQL)
ArQule (ARQL) in Focus: Stock Moves 15.6% Higher
by Zacks Equity Research
Shares of ArQule (ARQL) rose nearly 16% yesterday.
Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1%
by Zacks Equity Research
Galectin Therapeutics Inc. (GALT) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.
ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher
by Zacks Equity Research
ArQule, Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 7% on the day.